Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1668243 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $41.09Day +1.58%Mkt cap $2.0B1Y +113.8%Off 52W high −6.5%Vol (1Y) 66.1%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,317 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest11.7% of sh out |
| Days to cover6.9d |
| 13F net flow (QoQ)−4.70% |
| Top-10 13F concentration51.0% |
| Next report (est.)2026-08-05 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$140.5M |
| Earnings (TTM)-$133.2M |
| Net margin−139.8% |
| Sales growth 3Y19.5% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+75.4% |
| 1Y+113.8% |
| 3Y+89.7% |
| 5Y+165.1% |
| Since incept. (ann.)+12.4% |
Total return through 2026-07-30 · series begins 2017-05-04. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)66.1% |
| Ann. volatility (3Y)83.0% |
| Sharpe (1Y)1.53 |
| Sharpe (3Y)0.67 |
| Max drawdown (1Y)−42.2% |
| Max drawdown (3Y)−82.6% |
| Beta (3Y vs SPY)2.77 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 4.5M | $82M | 9.33% | +0.0% |
| BlackRock, Inc. | 2.8M | $51M | 5.85% | +9.4% |
| TORONTO DOMINION BANK | 2.6M | $47M | 5.38% | new |
| MORGAN STANLEY | 2.6M | $46M | 5.26% | −0.1% |
| Kynam Capital Management, LP | 2.2M | $40M | 4.62% | new |
| Jefferies Financial Group Inc. | 2.2M | $40M | 4.52% | +0.0% |
| Paradigm Biocapital Advisors LP | 1.7M | $31M | 3.50% | −61.9% |
| ACORN CAPITAL ADVISORS, LLC | 1.7M | $30M | 3.44% | +15.5% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-06 | — | — | $51.0M | +151.6% |
| 2025-12-31 | 2026-03-02 | — | — | $37.8M | +54.0% |
| 2025-09-30 | 2025-11-06 | — | — | $27.5M | +9.0% |
| 2025-06-30 | 2025-08-07 | — | — | $24.2M | +10.8% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-05 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Jelmyto 86% · Zusduri 14%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
